[go: up one dir, main page]

ES2421731T3 - Composición y procedimiento para el tratamiento de MRSA - Google Patents

Composición y procedimiento para el tratamiento de MRSA

Info

Publication number
ES2421731T3
ES2421731T3 ES09790912T ES09790912T ES2421731T3 ES 2421731 T3 ES2421731 T3 ES 2421731T3 ES 09790912 T ES09790912 T ES 09790912T ES 09790912 T ES09790912 T ES 09790912T ES 2421731 T3 ES2421731 T3 ES 2421731T3
Authority
ES
Spain
Prior art keywords
composition
treatment
mrsa
procedure
chlorhexidine digluconate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09790912T
Other languages
English (en)
Inventor
Cale Street
Nicolas Loebel
Lisa Pedigo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ondine International Ltd
Original Assignee
Ondine International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ondine International Ltd filed Critical Ondine International Ltd
Application granted granted Critical
Publication of ES2421731T3 publication Critical patent/ES2421731T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición adecuada para reducir microbios que causan enfermedades que comprende:un fotosensibilizador; digluconato de clorhexidina, siendo la concentración del digluconato de clorhexidina superior a un 0,01% e inferior a un 2% v/v; y un vehículo farmacéuticamente aceptable; estando destinada la composición a la desinfección fotodinámica de un sitio de tratamiento que contiene losmicrobios.
ES09790912T 2008-08-01 2009-07-29 Composición y procedimiento para el tratamiento de MRSA Active ES2421731T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8557708P 2008-08-01 2008-08-01
US18606809P 2009-06-11 2009-06-11
PCT/US2009/052059 WO2010014676A1 (en) 2008-08-01 2009-07-29 Composition and method for treatment of mrsa

Publications (1)

Publication Number Publication Date
ES2421731T3 true ES2421731T3 (es) 2013-09-05

Family

ID=41277515

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09790912T Active ES2421731T3 (es) 2008-08-01 2009-07-29 Composición y procedimiento para el tratamiento de MRSA

Country Status (11)

Country Link
US (2) US8247406B2 (es)
EP (1) EP2323643B1 (es)
JP (1) JP2011529898A (es)
KR (1) KR101631335B1 (es)
CN (1) CN102112120B (es)
AU (1) AU2009276679B2 (es)
CA (1) CA2732307C (es)
ES (1) ES2421731T3 (es)
GB (1) GB2475005A (es)
IL (1) IL210997A (es)
WO (1) WO2010014676A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2323643B1 (en) 2008-08-01 2013-05-08 Ondine International Ltd. Composition and method for treatment of mrsa
JP5651426B2 (ja) * 2010-10-25 2015-01-14 阪田　功 クロリン誘導体
WO2012085257A1 (en) * 2010-12-22 2012-06-28 Ortner Cleanroom Engineering Gmbh Photodynamic control of microbial growth on surfaces
WO2012158483A2 (en) 2011-05-16 2012-11-22 Avery Dennison Corporation Adhesive containing microparticles
EP2780005A1 (en) * 2011-11-17 2014-09-24 Avery Dennison Corporation Controlled release of active using ph
US11497932B2 (en) 2012-04-05 2022-11-15 Light Line Medical, Inc. Electromagnetic radiation delivery and monitoring system and methods for preventing, reducing and/or eliminating catheter-related infections during institutional or in-home use
JP6433436B2 (ja) 2013-02-07 2018-12-05 エーブリー デニソン コーポレイション 改善された性質を有する抗菌性接着剤
EP2968014B1 (en) 2013-03-15 2019-04-24 Avery Dennison Corporation Transparent cover dressing application system and inclusion of label strip
WO2015089421A1 (en) 2013-12-12 2015-06-18 Innovation Technologies, Inc. Materials and methods for controlling infections
US10016375B2 (en) 2013-12-12 2018-07-10 Paul J. Rucinski Materials and methods for controlling infections
EP3789014A1 (en) 2014-06-05 2021-03-10 Avery Dennison Corporation Articles with active agent concentrated at the substrate contacting surface and related methods
US11479799B2 (en) 2014-09-16 2022-10-25 President And Fellows Of Harvard College Engineered water nanostructures (EWNS) and uses thereof
CN108463249A (zh) * 2016-02-04 2018-08-28 富士胶片株式会社 光线力学疗法用组合物、治疗方法、杀菌系统及杀菌系统的工作方法
US11137140B2 (en) 2017-10-04 2021-10-05 Raytheon Technologies Corporation Dilution holes with ridge feature for gas turbine engines
GB201718631D0 (en) 2017-11-10 2017-12-27 Pci Biotech As Method
WO2019113096A1 (en) 2017-12-05 2019-06-13 BioPlx, Inc. Methods and compositions to prevent microbial infection
JP7622946B2 (ja) * 2019-06-03 2025-01-28 眞人 光永 殺菌剤
US20240245774A1 (en) * 2023-01-25 2024-07-25 Ondine International Ag Composition and a photodynamic therapeutic method to shorten infectivity period and to induce sustained humoral and cellular t-cell responses against a targeted antigen in infected individuals

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN066795A0 (en) * 1995-01-20 1995-02-16 Macquarie Research Limited Method of repair
US20020022660A1 (en) * 1998-01-20 2002-02-21 Hanuman B. Jampani Deep penetrating antimicrobial compositions
US6607522B1 (en) * 2000-03-16 2003-08-19 General Hospital Corporation Methods for tissue welding using laser-activated protein solders
GB0023367D0 (en) * 2000-09-23 2000-11-08 Univ Leeds Photosensitisers
GB0113121D0 (en) * 2001-05-30 2001-07-18 Univ Leeds Biologically active photosensitisers
US20080260650A1 (en) * 2004-10-28 2008-10-23 The General Hospital Corporation Methods of Detection and Therapy of Inflamed Tissues Using Immune Modulation
WO2008070023A2 (en) * 2006-12-01 2008-06-12 Pond Gary J Improved dental irrigant
US20090093470A1 (en) * 2007-10-08 2009-04-09 Ondine International, Ltd. Photodynamic therapy process and photosensitizer compositions therefor
EP2323643B1 (en) 2008-08-01 2013-05-08 Ondine International Ltd. Composition and method for treatment of mrsa

Also Published As

Publication number Publication date
US20120277660A1 (en) 2012-11-01
CN102112120A (zh) 2011-06-29
EP2323643A1 (en) 2011-05-25
CA2732307A1 (en) 2010-02-04
IL210997A0 (en) 2011-04-28
GB201103465D0 (en) 2011-04-13
CA2732307C (en) 2017-01-24
KR101631335B1 (ko) 2016-06-16
EP2323643B1 (en) 2013-05-08
GB2475005A (en) 2011-05-04
US20100029779A1 (en) 2010-02-04
IL210997A (en) 2016-05-31
HK1158522A1 (en) 2012-07-20
WO2010014676A1 (en) 2010-02-04
JP2011529898A (ja) 2011-12-15
US8247406B2 (en) 2012-08-21
US8618091B2 (en) 2013-12-31
AU2009276679B2 (en) 2013-05-16
KR20110055523A (ko) 2011-05-25
AU2009276679A2 (en) 2011-02-03
CN102112120B (zh) 2013-01-23
AU2009276679A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
ES2421731T3 (es) Composición y procedimiento para el tratamiento de MRSA
EA201690904A1 (ru) Антибактериальная композиция для ротовой полости
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
EA021554B9 (ru) Органические соединения и их применение для лечения hcv инфекции
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
PE20090113A1 (es) Compuestos triciclicos como moduladores del receptor de glucocorticoides, composiciones y procedimientos
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
ECSP109897A (es) Composiciones terapeuticas y usos de las mismas
EP2452935A3 (en) Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
MX366175B (es) Composiciones fosfolipidicas terapeuticas concentradas.
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
EA201200253A1 (ru) Композиция для лечения муковисцидоза
MX2011001005A (es) Uso de derivados de tetraquis (n-alquilpiridinio)-porfirina para eliminacion de microbios o prevencion del crecimiento.
CO6640335A2 (es) Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
CL2010001260A1 (es) Composicion farmaceutica que comprende una sal de estroncio y vitamina d y una ciclodextrina, donde la relacion masica entre la cantidad de vitamina d y la cantidad de ciclodextrina esta comprendida entre 1/40 y 1/800, util para tratar o prevenir osteoporosis.
CL2008001560A1 (es) Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico.
DOP2006000235A (es) Derivados de acidos dicarboxilicos y su uso
GT200600260A (es) Derivados de benzamida y usos relacionados con los mismos
MX384378B (es) Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.
CL2009000727A1 (es) Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras.
CO6511222A2 (es) Derivado de idenona y composición famacéutica que comprende el mismo
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc